Literature DB >> 20123888

Results of a surgical resection of pulmonary metastasis from malignant head and neck tumor.

Akira Haro1, Tokujiro Yano, Tsukihisa Yoshida, Kensaku Ito, Yosuke Morodomi, Fumihiro Shoji, Torahiko Nakashima, Yoshihiko Maehara.   

Abstract

There have been only a few reports about a surgical resection of pulmonary metastasis from malignant head and neck tumor. Here we investigate the survival after a pulmonary metastasectomy, and discuss the prognostic factors. We retrospectively reviewed 25 patients who underwent a pulmonary metastasectomy from malignant head and neck tumor at Kyushu University Hospital from 1981 through 2008. We assessed the five year overall survival by the Kaplan-Meier method and the log-rank (Mantel-Cox) test using the Stat View software program. The three- or five-year overall survival after a metastasectomy was 53.3% and 50.0%, respectively. We investigated the clinico-pathological prognostic factors including gender, age, histology, disease free interval, number or size of pulmonary metastatic tumors, and the operative procedure. Both age (older than 60 years) (P=0.0189) and pulmonary metastases from squamous cell carcinomas in either oral cavity or pharyngeal region (P=0.0002) were identified to be adverse prognostic factors. To obtain a long survival, a positive surgical resection is considered to be an effective and standard treatment for pulmonary metastasis from malignant head and neck tumor. It is also necessary, however, to elucidate fully the primary site and histology of such pulmonary metastasis. 2010 Published by European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20123888     DOI: 10.1510/icvts.2009.219766

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  8 in total

Review 1.  Treatment Strategy for Distant Synchronous Metastatic Head and Neck Squamous Cell Carcinoma.

Authors:  Eliane Tang; Lucien Lahmi; Nicolas Meillan; Gianandrea Pietta; Sébastien Albert; Philippe Maingon
Journal:  Curr Oncol Rep       Date:  2019-11-14       Impact factor: 5.075

2.  [Surgical therapy of lung metastases from head and neck cancer].

Authors:  S Macherey; S F Preuss; F Doerr; S Grönke; M Heldwein; A Quaas; T Zander; K Hekmat
Journal:  HNO       Date:  2014-12       Impact factor: 1.284

Review 3.  Approach to the Patient with Recurrent/Metastatic Disease.

Authors:  Joël Guigay; Esma Sâada-Bouzid; Frédéric Peyrade; Cécile Michel
Journal:  Curr Treat Options Oncol       Date:  2019-06-25

Review 4.  Pulmonary metastasectomy: an overview.

Authors:  Francesco Petrella; Cristina Diotti; Arianna Rimessi; Lorenzo Spaggiari
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

5.  Factors determining the survival of nasopharyngeal carcinoma with lung metastasis alone: does combined modality treatment benefit?

Authors:  Xun Cao; Li-Ru He; Fang-Yun Xie; You-Fang Chen; Zhe-Sheng Wen
Journal:  BMC Cancer       Date:  2011-08-24       Impact factor: 4.430

Review 6.  Patients with Pulmonary Metastases from Head and Neck Cancer Benefit from Pulmonary Metastasectomy, A Systematic Review.

Authors:  Georg Schlachtenberger; Fabian Doerr; Hruy Menghesha; Patrick Lauinger; Philipp Wolber; Anton Sabashnikov; Aron-Frederik Popov; Sascha Macherey-Meyer; Gerardus Bennink; Jens P Klussmann; Thorsten Wahlers; Khosro Hekmat; Mathias B Heldwein
Journal:  Medicina (Kaunas)       Date:  2022-07-27       Impact factor: 2.948

7.  Survival predictors after resection of lung metastases of head or neck cancers.

Authors:  Masaya Yotsukura; Tomonari Kinoshita; Mitsutomo Kohno; Keisuke Asakura; Ikuo Kamiyama; Katsura Emoto; Yuichiro Hayashi; Takashi Ohtsuka
Journal:  Thorac Cancer       Date:  2015-01-26       Impact factor: 3.500

8.  Effect of STAT5 silenced by siRNA on proliferation apoptosis and invasion of esophageal carcinoma cell line Eca-109.

Authors:  Qian Yang; Min Li; Tao Wang; Hong Xu; Wenqiao Zang; Guoqiang Zhao
Journal:  Diagn Pathol       Date:  2013-08-05       Impact factor: 2.644

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.